{
    "symbol": "ROIV",
    "quarter": 3,
    "year": 2022,
    "date": "2022-02-14 14:12:02",
    "content": " I just want to highlight that 2022 was an incredibly exciting year for us, again, with the FDA approval decision for tapinarof expected in the second quarter, with top line data coming in the first half of next year, with batoclimab getting into multiple new programs in the clinic, with data expected \u2013 and what we shared is we have it on additional patients in our sickle cell gene therapy event, we didn\u2019t spend any time today talking about it, but we continue to enroll patients in our Phase 1/2 trial in sickle cell disease and look forward to sharing more updates on that program over the course of this year, also look forward to discussing the initiation of our Phase 2 trial in sarcoidosis Kinevant."
}